Zosano Pharma Corporation / Fundamentals
Income statement
- Net revenue
€565.42K - Cost of goods sold
€617.76K - Gross profit
-€52.34K - SG&A expenses
€9.16M - R&D expenses
€17.27M - EBITDA
-€45.87M - D&A
€1.34M - EBIT
-€48.75M - Interest expenses
€141.57K - EBT
-€47.35M - Tax expenses
€1.65M - Net income
-€47.46M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€22.18M - Changes in working capital
-€2.41M - Operating cash flow
-€24.60M - Capex
€1.93M - Other investing cash flow
€0.00 - Net investing cash flow
-€1.93M - Total cash dividends paid
€0.00 - Issuance of common stock
€20.86M - Debt repayment
€0.00 - Other financing cash flow
€15.07M - Net financing cash flow
€15.07M - Foreign exchange effects
€0.00 - Net change in cash
-€11.46M - Cash at end of period
€12.00M - Free cash flow
-€22.67M
Balance sheet
- Cash and cash equivalents
€11.61M - Cash and short-term investments
€11.61M - Total receivables
€91.81K - Inventory
€0.00 - Other current assets
€1.71M - Total current assets
€13.41M - Property, plant & equipment
€8.89M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€390.39K - Total non-current assets
€9.28M - Total assets
€22.69M - Accounts payable
€3.19M - Short-term debt
€2.90M - Other current liabilities
€2.07M - Total current liabilities
€8.35M - Long-term debt
€2.28M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€2.28M - Total liabilities
€10.63M - Common stock
€0.00 - Retained earnings
-€339.36M - Other equity
€0.00 - Total equity
€12.06M - Total liabilities and shareholders' equity
€22.69M
Company information
- Market capitalization
€0.00 - Employees
40
Company ratios
- Gross margin
-
-9.3% Much better than peer group: -695,693,581,436.6% - EBITDA margin
-
-8,112.4% Much better than peer group: -3,382,197,822,206.5% - EBIT margin
-
-8,622.3% Much better than peer group: -3,405,203,244,215.2% - EBT margin
-
-8,375.1% Much better than peer group: -3,351,176,574,744.5% - Net margin
-
-8,394.2% Much better than peer group: -3,351,176,574,757.0% - ROE
-
-393.6% Much worse than peer group: 180.6% - ROA
-
-209.2% Much better than peer group: -888.8% - Asset turnover
-
2.5% Much worse than peer group: 40.8% - FCF margin
-
-4,692.3% Much better than peer group: -3,324,083,078,055.6% - FCF yield
0.0% - Efficiency ratio
8,212.4% - Net sales per employee
-
€14.14K - Net income per employee
-
-€1.19M